



Clinical trial results:

A Multicenter, open, randomized, controlled phase IIb trial evaluating efficacy and tolerability of GRASPA (L-asparaginase encapsulated in red blood cells, eryaspase) plus low-dose cytarabine versus low-dose cytarabine alone, in treatment of newly diagnosed acute myeloid leukemia (AML) elderly patients, unfit for intensive chemotherapy. ENFORCE 1 study.

Summary

EudraCT number	2012-002026-78
Trial protocol	IT FI DE ES
Global end of trial date	10 November 2017

Results information

Result version number	v1 (current)
This version publication date	21 March 2020
First version publication date	21 March 2020

Trial information

Trial identification

Sponsor protocol code	GRASPA-AML 2012-01
-----------------------	--------------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01810705
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Erytech Pharma
Sponsor organisation address	60 avenue Rockefeller, Bâtiment Adenine, Lyon, France, 69008
Public contact	Clinical Operations. Jean Baptiste Bertrand, ERYTECH Pharma, 33 4 78 74 44 38, jb.bertrand@erytech.com
Scientific contact	Jason Cain, ERYTECH Pharma, +1 857 285 24 15, ason.cain@erytech.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	19 June 2018
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	10 November 2017
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate Overall Survival (OS) in AML patients who were 65-85 years old and unfit for intensive chemotherapy, when treated with GRASPA (L-asparaginase encapsulated in erythrocytes) plus low-dose cytarabine compared to low-dose cytarabine alone

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements related to safety of trial subjects were also followed during the conduct of the trial.

An independent DSMB reviewed the interim results from the study as well as safety and futility on a regular basis. The DSMB had the potential to stop the study for overwhelming evidence of benefit or futility.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	11 March 2013
Long term follow-up planned	Yes
Long term follow-up rationale	Safety, Efficacy
Long term follow-up duration	24 Months
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	France: 110
Country: Number of subjects enrolled	Norway: 3
Country: Number of subjects enrolled	Spain: 3
Country: Number of subjects enrolled	Finland: 3
Country: Number of subjects enrolled	Germany: 1
Country: Number of subjects enrolled	Italy: 3
Worldwide total number of subjects	123
EEA total number of subjects	123

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	121
85 years and over	2

Subject disposition

Recruitment

Recruitment details:

First patient in: 11MAR2013

Last patient in: 02AUG2016

Territories: Europe (France, Italy, Spain, Finland, Norway, Germany)

Pre-assignment

Screening details:

- Patient \geq 65 years old and \leq 85 years old
- Newly diagnosed Acute Myeloid Leukemia (AML) or post myelodysplastic syndrome diagnosed within 6 months prior to study enrollment
- Unfit for intensive chemotherapy (at risk to suffer treatment related pejorative toxicities /early death)
- ECOG performance status \leq 2

Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	low-dose cytarabine + GRASPA

Arm description:

In the experimental group, the patients will receive one administration of GRASPA (100 IU/kg) at Day 11 in combination with subcutaneous low-dose cytarabine as 40 mg daily (either one single dose of 40 mg or 20 mg twice daily according to local practice) for 10 consecutive days, every 28 days, for duration up to 24 months.

Arm type	Experimental
Investigational medicinal product name	GRASPA
Investigational medicinal product code	
Other name	Eryaspase
Pharmaceutical forms	Suspension for injection
Routes of administration	Intravenous use

Dosage and administration details:

In the experimental group, the patients will receive one administration of GRASPA (100 IU/kg) at Day 11 in combination with subcutaneous low-dose cytarabine as 40 mg daily (either one single dose of 40 mg or 20 mg twice daily according to local practice) for 10 consecutive days, every 28 days, for duration up to 24 months.

Arm title	low-dose cytarabine alone
------------------	---------------------------

Arm description:

In the control arm, patients will be treated with subcutaneous low-dose cytarabine as 40 mg daily (either one single dose of 40 mg or 20 mg twice daily according to local practice) for 10 consecutive days, every 28 days, for duration up to 24 months. Each period of 28 days constitute a cycle of chemotherapy.

Arm type	Standard polychemotherapy with low dose cytarabine
No investigational medicinal product assigned in this arm	

Number of subjects in period 1	low-dose cytarabine + GRASPA	low-dose cytarabine alone
Started	83	40
Completed	10	5
Not completed	73	35
Consent withdrawn by subject	1	1
Exclusion criteria (randomized in error)	2	-
Death (all causes)	70	34

Baseline characteristics

Reporting groups

Reporting group title	low-dose cytarabine + GRASPA
-----------------------	------------------------------

Reporting group description:

In the experimental group, the patients will receive one administration of GRASPA (100 IU/kg) at Day 11 in combination with subcutaneous low-dose cytarabine as 40 mg daily (either one single dose of 40 mg or 20 mg twice daily according to local practice) for 10 consecutive days, every 28 days, for duration up to 24 months.

Reporting group title	low-dose cytarabine alone
-----------------------	---------------------------

Reporting group description:

In the control arm, patients will be treated with subcutaneous low-dose cytarabine as 40 mg daily (either one single dose of 40 mg or 20 mg twice daily according to local practice) for 10 consecutive days, every 28 days, for duration up to 24 months. Each period of 28 days constitute a cycle of chemotherapy.

Reporting group values	low-dose cytarabine + GRASPA	low-dose cytarabine alone	Total
Number of subjects	83	40	123
Age categorical Units: Subjects			
65-85 years	83	40	123
Age continuous Units: years			
arithmetic mean	77.2	76.0	
standard deviation	± 4.17	± 4.54	-
Gender categorical Units: Subjects			
Female	37	16	53
Male	46	24	70

End points

End points reporting groups

Reporting group title	low-dose cytarabine + GRASPA
-----------------------	------------------------------

Reporting group description:

In the experimental group, the patients will receive one administration of GRASPA (100 IU/kg) at Day 11 in combination with subcutaneous low-dose cytarabine as 40 mg daily (either one single dose of 40 mg or 20 mg twice daily according to local practice) for 10 consecutive days, every 28 days, for duration up to 24 months.

Reporting group title	low-dose cytarabine alone
-----------------------	---------------------------

Reporting group description:

In the control arm, patients will be treated with subcutaneous low-dose cytarabine as 40 mg daily (either one single dose of 40 mg or 20 mg twice daily according to local practice) for 10 consecutive days, every 28 days, for duration up to 24 months. Each period of 28 days constitute a cycle of chemotherapy.

Subject analysis set title	Intention-to-Treat efficacy population
----------------------------	--

Subject analysis set type	Intention-to-treat
---------------------------	--------------------

Subject analysis set description:

The Intention-to-Treat (ITT) efficacy population comprised of all randomised patients in the groups to which they were randomly assigned, regardless of their adherence to the entry criteria, the treatment they actually received, or subsequent withdrawal from treatment or deviation from the protocol.

Subject analysis set title	Per Protocol efficacy population
----------------------------	----------------------------------

Subject analysis set type	Per protocol
---------------------------	--------------

Subject analysis set description:

The Per-Protocol (PP) efficacy population comprised all patients from the ITT population without major protocol deviations who received trial product and completed at least one course of treatment

Subject analysis set title	Safety population
----------------------------	-------------------

Subject analysis set type	Safety analysis
---------------------------	-----------------

Subject analysis set description:

The Safety population comprised all patients who received at least one administration of trial products. Data analysis for the Safety population will be according to treatment received. All evaluations of safety will be undertaken based on this population.

Primary: Overall survival (OS)

End point title	Overall survival (OS)
-----------------	-----------------------

End point description:

OS was to be assessed by measuring time elapsed between randomisation and death for any cause. Any patient not known to have died at the time of analysis is censored based on the last recorded date on which the patient was known to be alive

End point type	Primary
----------------	---------

End point timeframe:

Whole trial period

End point values	low-dose cytarabine + GRASPA	low-dose cytarabine alone		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	83	40		
Units: months				
median (confidence interval 95%)	4.8 (3.1 to 7.0)	6.4 (3.6 to 10.7)		

Statistical analyses

Statistical analysis title	Analysis of OS
Statistical analysis description:	
The p-value for the time to event analysis is associated with the stratified log-rank statistic. The stratification factor is performance status (0-1, 2). Hazard ratio and 95% confidence interval are estimated from the stratified Cox model. The stratification factor is performance status (0-1, 2).	
Comparison groups	low-dose cytarabine + GRASPA v low-dose cytarabine alone
Number of subjects included in analysis	123
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.827 ^[1]
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	1.05
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.69
upper limit	1.59

Notes:

[1] - Not statistically significant. No evidence to support treatment differences for OS

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events are collected from signature of the informed consent from first patient and until 4 months after last GRASPA/ low-dose cytarabine administration of last patient.

Adverse event reporting additional description:

Serious adverse events reported in this report (details of serious adverse events table) are treatment emergent serious adverse events with threshold 5.0 %.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	20.0

Reporting groups

Reporting group title	low-dose cytarabine alone
-----------------------	---------------------------

Reporting group description: -

Reporting group title	low-dose cytarabine + GRASPA
-----------------------	------------------------------

Reporting group description: -

Serious adverse events	low-dose cytarabine alone	low-dose cytarabine + GRASPA	
Total subjects affected by serious adverse events			
subjects affected / exposed	32 / 39 (82.05%)	74 / 81 (91.36%)	
number of deaths (all causes)	34	70	
number of deaths resulting from adverse events	16	35	
General disorders and administration site conditions			
General physical health deterioration			
subjects affected / exposed	3 / 39 (7.69%)	10 / 81 (12.35%)	
occurrences causally related to treatment / all	1 / 3	1 / 12	
deaths causally related to treatment / all	1 / 3	0 / 7	
Pyrexia			
subjects affected / exposed	2 / 39 (5.13%)	7 / 81 (8.64%)	
occurrences causally related to treatment / all	1 / 2	4 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Febrile bone marrow aplasia			
subjects affected / exposed	2 / 39 (5.13%)	8 / 81 (9.88%)	
occurrences causally related to treatment / all	0 / 2	5 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	

Febrile neutropenia			
subjects affected / exposed	3 / 39 (7.69%)	7 / 81 (8.64%)	
occurrences causally related to treatment / all	2 / 5	3 / 7	
deaths causally related to treatment / all	0 / 0	0 / 1	
Anaemia			
subjects affected / exposed	1 / 39 (2.56%)	7 / 81 (8.64%)	
occurrences causally related to treatment / all	1 / 1	4 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hemorrhagic Events			
subjects affected / exposed	1 / 39 (2.56%)	6 / 81 (7.41%)	
occurrences causally related to treatment / all	0 / 1	2 / 6	
deaths causally related to treatment / all	0 / 1	1 / 2	
Pancytopenia			
subjects affected / exposed	1 / 39 (2.56%)	5 / 81 (6.17%)	
occurrences causally related to treatment / all	0 / 1	6 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 39 (0.00%)	6 / 81 (7.41%)	
occurrences causally related to treatment / all	0 / 0	6 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Lung disorder			
subjects affected / exposed	3 / 39 (7.69%)	6 / 81 (7.41%)	
occurrences causally related to treatment / all	1 / 3	3 / 6	
deaths causally related to treatment / all	0 / 1	0 / 0	
Infections and infestations			
Sepsis			
subjects affected / exposed	6 / 39 (15.38%)	12 / 81 (14.81%)	
occurrences causally related to treatment / all	1 / 6	5 / 13	
deaths causally related to treatment / all	1 / 3	2 / 6	
Septic shock			

subjects affected / exposed	6 / 39 (15.38%)	7 / 81 (8.64%)	
occurrences causally related to treatment / all	2 / 6	1 / 7	
deaths causally related to treatment / all	2 / 6	1 / 7	
Bronchopulmonary aspergillosis			
subjects affected / exposed	2 / 39 (5.13%)	4 / 81 (4.94%)	
occurrences causally related to treatment / all	0 / 2	1 / 5	
deaths causally related to treatment / all	0 / 1	0 / 2	
Lung infection			
subjects affected / exposed	2 / 39 (5.13%)	1 / 81 (1.23%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infection			
subjects affected / exposed	2 / 39 (5.13%)	0 / 81 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	low-dose cytarabine alone	low-dose cytarabine + GRASPA	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	39 / 39 (100.00%)	80 / 81 (98.77%)	
Vascular disorders			
Epistaxis			
subjects affected / exposed	6 / 39 (15.38%)	10 / 81 (12.35%)	
occurrences (all)	6	12	
Hypertension			
subjects affected / exposed	4 / 39 (10.26%)	10 / 81 (12.35%)	
occurrences (all)	5	12	
Purpura			
subjects affected / exposed	2 / 39 (5.13%)	5 / 81 (6.17%)	
occurrences (all)	2	5	
Haematoma			
subjects affected / exposed	2 / 39 (5.13%)	4 / 81 (4.94%)	
occurrences (all)	2	4	
Petechiae			

subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	3 / 81 (3.70%) 3	
General disorders and administration site conditions			
asthenia			
subjects affected / exposed	18 / 39 (46.15%)	28 / 81 (34.57%)	
occurrences (all)	20	34	
Oedema peripheral			
subjects affected / exposed	9 / 39 (23.08%)	13 / 81 (16.05%)	
occurrences (all)	10	17	
Pain			
subjects affected / exposed	2 / 39 (5.13%)	8 / 81 (9.88%)	
occurrences (all)	2	8	
Injection site haematoma			
subjects affected / exposed	2 / 39 (5.13%)	5 / 81 (6.17%)	
occurrences (all)	2	5	
Pyrexia			
subjects affected / exposed	13 / 39 (33.33%)	26 / 81 (32.10%)	
occurrences (all)	27	50	
General physical health deterioration			
subjects affected / exposed	3 / 39 (7.69%)	4 / 81 (4.94%)	
occurrences (all)	3	4	
Immune system disorders			
Alloimmunisation			
subjects affected / exposed	1 / 39 (2.56%)	16 / 81 (19.75%)	
occurrences (all)	1	16	
Allergic transfusion reaction			
subjects affected / exposed	2 / 39 (5.13%)	5 / 81 (6.17%)	
occurrences (all)	2	5	
Hypersensitivity			
subjects affected / exposed	0 / 39 (0.00%)	8 / 81 (9.88%)	
occurrences (all)	0	14	
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	8 / 39 (20.51%)	11 / 81 (13.58%)	
occurrences (all)	9	14	
Cough			

subjects affected / exposed occurrences (all)	7 / 39 (17.95%) 7	9 / 81 (11.11%) 10	
Acute pulmonary oedema subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	0 / 81 (0.00%) 0	
Oropharyngeal pain subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	0 / 81 (0.00%) 0	
Lung disorder subjects affected / exposed occurrences (all)	3 / 39 (7.69%) 3	3 / 81 (3.70%) 3	
Psychiatric disorders			
Anxiety subjects affected / exposed occurrences (all)	4 / 39 (10.26%) 4	11 / 81 (13.58%) 12	
Depression subjects affected / exposed occurrences (all)	3 / 39 (7.69%) 3	5 / 81 (6.17%) 5	
Confusional state subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	4 / 81 (4.94%) 5	
Investigations			
Blood albumin decreased subjects affected / exposed occurrences (all)	6 / 39 (15.38%) 8	24 / 81 (29.63%) 29	
Pancreatic enzymes abnormal subjects affected / exposed occurrences (all)	5 / 39 (12.82%) 5	20 / 81 (24.69%) 31	
Transaminases increased subjects affected / exposed occurrences (all)	6 / 39 (15.38%) 10	15 / 81 (18.52%) 40	
Antithrombin III decreased subjects affected / exposed occurrences (all)	3 / 39 (7.69%) 3	17 / 81 (20.99%) 22	
Gamma-glutamyltransferase increased			

subjects affected / exposed	5 / 39 (12.82%)	15 / 81 (18.52%)	
occurrences (all)	5	18	
Weight decreased			
subjects affected / exposed	7 / 39 (17.95%)	9 / 81 (11.11%)	
occurrences (all)	7	9	
Blood Creatinine increased			
subjects affected / exposed	3 / 39 (7.69%)	12 / 81 (14.81%)	
occurrences (all)	3	15	
Blood chloride increased			
subjects affected / exposed	2 / 39 (5.13%)	11 / 81 (13.58%)	
occurrences (all)	3	15	
Blood urea increased			
subjects affected / exposed	4 / 39 (10.26%)	9 / 81 (11.11%)	
occurrences (all)	6	9	
Blood lactate dehydrogenase increased			
subjects affected / exposed	2 / 39 (5.13%)	7 / 81 (8.64%)	
occurrences (all)	2	8	
Blood alkaline phosphatase increased			
subjects affected / exposed	3 / 39 (7.69%)	5 / 81 (6.17%)	
occurrences (all)	3	5	
Blood chloride decreased			
subjects affected / exposed	3 / 39 (7.69%)	5 / 81 (6.17%)	
occurrences (all)	3	6	
Prothrombin time ratio decreased			
subjects affected / exposed	0 / 39 (0.00%)	8 / 81 (9.88%)	
occurrences (all)	0	10	
Activated partial thromboplastin time prolonged			
subjects affected / exposed	1 / 39 (2.56%)	6 / 81 (7.41%)	
occurrences (all)	1	7	
Injury, poisoning and procedural complications			
fall			
subjects affected / exposed	3 / 39 (7.69%)	10 / 81 (12.35%)	
occurrences (all)	3	12	
Transfusion reaction			

subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1	7 / 81 (8.64%) 8	
Traumatic haematoma subjects affected / exposed occurrences (all)	3 / 39 (7.69%) 3	2 / 81 (2.47%) 2	
Food poisoning subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	0 / 81 (0.00%) 0	
Cardiac disorders Atrial fibrillation subjects affected / exposed occurrences (all)	5 / 39 (12.82%) 5	2 / 81 (2.47%) 2	
Cardiac failure subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1	4 / 81 (4.94%) 4	
Nervous system disorders Headache subjects affected / exposed occurrences (all)	6 / 39 (15.38%) 6	12 / 81 (14.81%) 13	
Blood and lymphatic system disorders thrombocytopenia subjects affected / exposed occurrences (all)	32 / 39 (82.05%) 84	59 / 81 (72.84%) 149	
Leukopenia subjects affected / exposed occurrences (all)	19 / 39 (48.72%) 31	41 / 81 (50.62%) 87	
Neutropenia subjects affected / exposed occurrences (all)	18 / 39 (46.15%) 34	35 / 81 (43.21%) 98	
Lymphopenia subjects affected / exposed occurrences (all)	6 / 39 (15.38%) 6	8 / 81 (9.88%) 9	
Leukocytosis subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	8 / 81 (9.88%) 8	
Bone marrow failure			

subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	2 / 81 (2.47%) 2	
Leukostasis syndrome subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1	0 / 81 (0.00%) 0	
Anaemia subjects affected / exposed occurrences (all)	34 / 39 (87.18%) 74	62 / 81 (76.54%) 170	
Hemorrhagic Events subjects affected / exposed occurrences (all)	9 / 39 (23.08%) 11	21 / 81 (25.93%) 23	
Febrile neutropenia subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1	7 / 81 (8.64%) 8	
Febrile bone marrow aplasia subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	4 / 81 (4.94%) 4	
Pancytopenia subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	3 / 81 (3.70%) 3	
Ear and labyrinth disorders Vertigo subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	4 / 81 (4.94%) 4	
Gastrointestinal disorders Nausea subjects affected / exposed occurrences (all)	15 / 39 (38.46%) 21	24 / 81 (29.63%) 57	
Diarrhoea subjects affected / exposed occurrences (all)	10 / 39 (25.64%) 12	24 / 81 (29.63%) 32	
Constipation subjects affected / exposed occurrences (all)	10 / 39 (25.64%) 11	18 / 81 (22.22%) 22	
Vomiting			

subjects affected / exposed occurrences (all)	5 / 39 (12.82%) 14	14 / 81 (17.28%) 27	
Stomatitis			
subjects affected / exposed occurrences (all)	3 / 39 (7.69%) 4	7 / 81 (8.64%) 7	
Aphthous ulcer			
subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1	9 / 81 (11.11%) 11	
Abdominal pain			
subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	4 / 81 (4.94%) 4	
Abdominal pain upper			
subjects affected / exposed occurrences (all)	3 / 39 (7.69%) 4	4 / 81 (4.94%) 4	
Haemorrhoids			
subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	5 / 81 (6.17%) 5	
Gastrooesophageal reflux disease			
subjects affected / exposed occurrences (all)	4 / 39 (10.26%) 4	1 / 81 (1.23%) 1	
Odynophagia			
subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	1 / 81 (1.23%) 1	
Gingival pain			
subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	0 / 81 (0.00%) 0	
Hepatobiliary disorders			
Hyperbilirubinaemia			
subjects affected / exposed occurrences (all)	5 / 39 (12.82%) 5	15 / 81 (18.52%) 25	
Hepatocellular injury			
subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 2	5 / 81 (6.17%) 5	
Skin and subcutaneous tissue disorders			
Erythema			

subjects affected / exposed occurrences (all)	3 / 39 (7.69%) 3	8 / 81 (9.88%) 10	
Pruritus subjects affected / exposed occurrences (all)	3 / 39 (7.69%) 3	4 / 81 (4.94%) 4	
Rash subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1	4 / 81 (4.94%) 4	
Renal and urinary disorders Renal failure subjects affected / exposed occurrences (all)	5 / 39 (12.82%) 5	12 / 81 (14.81%) 13	
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	4 / 39 (10.26%) 5	5 / 81 (6.17%) 7	
Pain in extremity subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	8 / 81 (9.88%) 10	
Back pain subjects affected / exposed occurrences (all)	3 / 39 (7.69%) 3	5 / 81 (6.17%) 6	
Musculoskeletal pain subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1	4 / 81 (4.94%) 4	
Myalgia subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	4 / 81 (4.94%) 5	
Infections and infestations Urinary tract infection subjects affected / exposed occurrences (all)	4 / 39 (10.26%) 6	12 / 81 (14.81%) 13	
Bronchitis subjects affected / exposed occurrences (all)	3 / 39 (7.69%) 5	6 / 81 (7.41%) 6	
Conjunctivitis			

subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	7 / 81 (8.64%) 7	
Oral candidiasis subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1	6 / 81 (7.41%) 6	
Fungal infection subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	2 / 81 (2.47%) 2	
Rhinitis subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	2 / 81 (2.47%) 2	
Gastroenteritis subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	0 / 81 (0.00%) 0	
Sepsis subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1	0 / 81 (0.00%) 0	
Bronchopulmonary aspergillosis subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1	2 / 81 (2.47%) 2	
Lung infection subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1	1 / 81 (1.23%) 1	
Infection subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	3 / 81 (3.70%) 3	
Metabolism and nutrition disorders			
Hypocalcaemia subjects affected / exposed occurrences (all)	9 / 39 (23.08%) 13	16 / 81 (19.75%) 19	
Decreased appetite subjects affected / exposed occurrences (all)	6 / 39 (15.38%) 8	5 / 81 (6.17%) 5	
Hyperglycaemia subjects affected / exposed occurrences (all)	3 / 39 (7.69%) 4	8 / 81 (9.88%) 10	

Hypertriglyceridaemia		
subjects affected / exposed	2 / 39 (5.13%)	8 / 81 (9.88%)
occurrences (all)	2	9
Hyperkalaemia		
subjects affected / exposed	3 / 39 (7.69%)	6 / 81 (7.41%)
occurrences (all)	3	8
Hypophosphataemia		
subjects affected / exposed	0 / 39 (0.00%)	7 / 81 (8.64%)
occurrences (all)	0	8
Hyperuricaemia		
subjects affected / exposed	2 / 39 (5.13%)	4 / 81 (4.94%)
occurrences (all)	2	4
Dehydration		
subjects affected / exposed	3 / 39 (7.69%)	2 / 81 (2.47%)
occurrences (all)	3	2
Hyperphosphataemia		
subjects affected / exposed	2 / 39 (5.13%)	3 / 81 (3.70%)
occurrences (all)	2	3
Vitamin D deficiency		
subjects affected / exposed	2 / 39 (5.13%)	1 / 81 (1.23%)
occurrences (all)	2	1
Hypokalaemia		
subjects affected / exposed	8 / 39 (20.51%)	25 / 81 (30.86%)
occurrences (all)	11	31
Hyponatraemia		
subjects affected / exposed	5 / 39 (12.82%)	17 / 81 (20.99%)
occurrences (all)	16	24

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
19 February 2013	Clarification of secondary endpoints. Correction of Pharmacokinetic and pharmacodynamic parameters procedures, and immunogenicity time points.
22 January 2014	Clarification inclusion/exclusion criteria. Clarification of study treatment administration.
21 July 2014	Addition of exclusion criteria to comply with BFArM demand. Clarification of inclusion criteria.
11 December 2015	Based on strong recommendation from several discussions with our coordinator PI as well as statistics experts, primary objective was changed to OS as considered more relevant for the pathology. PFS is now part of secondary objectives. Exploratory objectives were moved as secondary endpoints. Clarification of inclusion/exclusion criteria

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The study is not powered explicitly for OS, and statistical significance in favor of GRASPA plus low-dose cytarabine is not anticipated.

Notes: